David, I appreciate Brad's posts and it is unfortunate that you and others have driven both of us off this thread. I am a busy man and don't have time for the ridiculous. The 144s are for the venture capital players who have made huge profits. They almost always sell into offerings and their filings are not unusual. For a list of companies where the VCs filed 144s to sell their stock in connection with public offerings look at every successful biotec over the last 10 years.
AVIRs strength is not market manipulation but tremendous demand created by the companies road show presentations in connection with their offering which are obviously going very very well. The buyers are large institutional players and they have heard info on the road show that has them very excited. For your sake I hope you are not short.
-------------------- Symbol(s) 3888 & Date
Use Page Up, Page Down, +, -, or press U
--------------------------------------------------------------------------------
08/04 4:28P (DJ) =Aviron Up 20% In Response To Road Show Presentations >AVIR
Story 3888 (AVIR, I/BTC, I/MTC, N/DJN, N/DJWI, N/DJS, N/MMM, N/STK, M/TEC...)
NEW YORK (Dow Jones)--Shares of Aviron (AVIR) rose to a 52-week high Monday,
apparently fueled by positive sentiment from company presentations made for a
public offering.
Aviron rose 5 1/4, or 19.6%, to 32 on Nasdaq volume of 1.1 million, compared
with average daily volume of 275,900. The shares traded as high as 32 3/4
earlier, passing the 52-week high of 27 3/4 set just last week.
Sands Brothers & Co. analyst Michael Goldberg said the shares may be
rallying on the strength of Aviron's road show presentations to securities
firms in support of its upcoming public stock offering.
A Robertson Stephens & Co. trader agreed that the shares are probably rising
on the road show presentations, as she did not know of any other reason for
the stock activity.
As reported July 25, Aviron filed with the Securities and Exchange
Commission to offer 2.5 million common shares.
The Mountain View, Calif., biopharmaceutical firm plans to use proceeds for
clinical trials, manufacturing and marketing of its influenza vaccine, and for
research and development. The offering is being managed by Robertson Stephens
& Co.
Goldberg said the company has been making a series of presentations to
attract interest to its offering. Aviron made presentations in Europe last
|
